Guiyang Xintian Pharmaceutical Co Ltd
Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of new Chinese patent medicines in China. The company offers products in various dosage forms, including hard capsules, mixtures, granules, gels, tablets, syrups, wine preparation, dews preparations, and two Chinese medicine preparation production lines. Its products are used for the treatment of… Read more
Guiyang Xintian Pharmaceutical Co Ltd (002873) - Net Assets
Latest net assets as of September 2025: CN¥1.26 Billion CNY
Based on the latest financial reports, Guiyang Xintian Pharmaceutical Co Ltd (002873) has net assets worth CN¥1.26 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.09 Billion) and total liabilities (CN¥829.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.26 Billion |
| % of Total Assets | 60.36% |
| Annual Growth Rate | 17.17% |
| 5-Year Change | 44.24% |
| 10-Year Change | 427.9% |
| Growth Volatility | 32.63 |
Guiyang Xintian Pharmaceutical Co Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Guiyang Xintian Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Guiyang Xintian Pharmaceutical Co Ltd (2012–2024)
The table below shows the annual net assets of Guiyang Xintian Pharmaceutical Co Ltd from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.19 Billion | +7.31% |
| 2023-12-31 | CN¥1.11 Billion | -1.41% |
| 2022-12-31 | CN¥1.13 Billion | +26.81% |
| 2021-12-31 | CN¥890.44 Million | +7.50% |
| 2020-12-31 | CN¥828.30 Million | +16.87% |
| 2019-12-31 | CN¥708.76 Million | +7.29% |
| 2018-12-31 | CN¥660.59 Million | +6.19% |
| 2017-12-31 | CN¥622.11 Million | +122.81% |
| 2016-12-31 | CN¥279.21 Million | +23.37% |
| 2015-12-31 | CN¥226.31 Million | +18.80% |
| 2014-12-31 | CN¥190.50 Million | +21.05% |
| 2013-12-31 | CN¥157.38 Million | -11.81% |
| 2012-12-31 | CN¥178.44 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Guiyang Xintian Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 901.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥563.40 Million | 47.16% |
| Common Stock | CN¥244.10 Million | 20.43% |
| Other Comprehensive Income | CN¥180.92 Million | 15.14% |
| Other Components | CN¥206.30 Million | 17.27% |
| Total Equity | CN¥1.19 Billion | 100.00% |
Guiyang Xintian Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Guiyang Xintian Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SGL Carbon SE
PINK:SGLFF
|
$207.60 Million |
|
Chalice Mining Limited
PINK:CGMLF
|
$207.69 Million |
|
AUTOHELLAS S.A.NA EO 108
F:0AH1
|
$207.69 Million |
|
Contrel Technology Co Ltd
TWO:8064
|
$207.73 Million |
|
ABC arbitrage SA
PA:ABCA
|
$207.45 Million |
|
China-Singapore Suzhou Industrial Park Development Group Co Ltd
SHG:601512
|
$207.43 Million |
|
Western New England Bancorp Inc
NASDAQ:WNEB
|
$207.43 Million |
|
Impax Asset Management Group plc
PINK:IPXAF
|
$207.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guiyang Xintian Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,113,331,133 to 1,194,715,847, a change of 81,384,714 (7.3%).
- Net income of 52,322,877 contributed positively to equity growth.
- Dividend payments of 35,060,370 reduced retained earnings.
- Share repurchases of 129,479,757 reduced equity.
- Other comprehensive income increased equity by 106,832,208.
- Other factors increased equity by 86,769,756.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥52.32 Million | +4.38% |
| Dividends Paid | CN¥35.06 Million | -2.93% |
| Share Repurchases | CN¥129.48 Million | -10.84% |
| Other Comprehensive Income | CN¥106.83 Million | +8.94% |
| Other Changes | CN¥86.77 Million | +7.26% |
| Total Change | CN¥- | 7.31% |
Book Value vs Market Value Analysis
This analysis compares Guiyang Xintian Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.88x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 9.86x to 1.88x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥1.04 | CN¥10.22 | x |
| 2013-12-31 | CN¥0.91 | CN¥10.22 | x |
| 2014-12-31 | CN¥1.10 | CN¥10.22 | x |
| 2015-12-31 | CN¥1.31 | CN¥10.22 | x |
| 2016-12-31 | CN¥1.62 | CN¥10.22 | x |
| 2017-12-31 | CN¥3.03 | CN¥10.22 | x |
| 2018-12-31 | CN¥2.87 | CN¥10.22 | x |
| 2019-12-31 | CN¥3.12 | CN¥10.22 | x |
| 2020-12-31 | CN¥3.43 | CN¥10.22 | x |
| 2021-12-31 | CN¥5.29 | CN¥10.22 | x |
| 2022-12-31 | CN¥4.63 | CN¥10.22 | x |
| 2023-12-31 | CN¥4.55 | CN¥10.22 | x |
| 2024-12-31 | CN¥5.42 | CN¥10.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guiyang Xintian Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.10%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.63x
- Recent ROE (4.38%) is below the historical average (11.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 14.79% | 8.00% | 0.98x | 1.89x | CN¥8.55 Million |
| 2013 | 9.59% | 3.72% | 1.07x | 2.41x | CN¥-642.75K |
| 2014 | 17.39% | 7.29% | 0.97x | 2.46x | CN¥14.07 Million |
| 2015 | 18.56% | 8.05% | 1.05x | 2.21x | CN¥19.38 Million |
| 2016 | 20.44% | 9.01% | 1.15x | 1.97x | CN¥29.15 Million |
| 2017 | 10.63% | 9.70% | 0.80x | 1.38x | CN¥3.91 Million |
| 2018 | 10.77% | 10.22% | 0.71x | 1.49x | CN¥5.10 Million |
| 2019 | 10.10% | 9.24% | 0.71x | 1.53x | CN¥677.75K |
| 2020 | 8.76% | 9.66% | 0.49x | 1.85x | CN¥-10.28 Million |
| 2021 | 11.17% | 10.26% | 0.64x | 1.71x | CN¥10.43 Million |
| 2022 | 9.88% | 10.25% | 0.59x | 1.63x | CN¥-1.40 Million |
| 2023 | 7.26% | 8.48% | 0.50x | 1.72x | CN¥-30.46 Million |
| 2024 | 4.38% | 6.10% | 0.44x | 1.63x | CN¥-67.15 Million |
Industry Comparison
This section compares Guiyang Xintian Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guiyang Xintian Pharmaceutical Co Ltd (002873) | CN¥1.26 Billion | 14.79% | 0.66x | $207.58 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |